Manila Times Business
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the company’s pipeline and financial resources, it has retained Raymond James as its financial advisor to assist in evaluating a full range of strategic alternatives to advance its promising pipeline and to maximize value for all stakeholders. "With our best-in-class BLA-ready Fabry gene therapy program, di
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →